Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 7/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432413 | 0.86 | ROCK2 (0.36) | PDCD1CD274KMT2AROCK2AVPR2 | |
| SCHEMBL4910015 | 0.86 | OXTR (0.37) | KMT2AROCK2 | |
| SCHEMBL4907074 | 0.85 | KMT2A (0.34) | KMT2AROCK2AVPR1ASPTLC2KDM4E | |
| SCHEMBL4910971 | 0.84 | AVPR2 (0.38) | PDCD1CD274ROCK2AVPR2AVPR1A | |
| SCHEMBL4910044 | 0.84 | AVPR2 (0.38) | PDCD1CD274ROCK2AVPR2AVPR1A | |
| SCHEMBL4908675 | 0.84 | KDM4E (0.43) | AVPR2KDM4EALDH1A1 | |
| SCHEMBL4912248 | 0.81 | ALDH1A1 (0.39) | PDCD1CD274KMT2AROCK2AVPR2 | |
| SCHEMBL4913128 | 0.79 | PDCD1 (0.38) | PDCD1CD274ROCK2AVPR2AVPR1A | |
| SCHEMBL4907009 | 0.79 | ALDH1A1 (0.38) | PDCD1CD274KMT2AROCK2AVPR2 | |
| SCHEMBL4907017 | 0.79 | ROCK2 (0.38) | PDCD1CD274KMT2AROCK2AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | PDCD1 3023/4885CD274 2327/4885KMT2A 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.